However, while not significant, patients with variants in BBS10 did have a numerically greater reduction in MetS-Z-BMI scores after setmelanotide treatment compared with patients with variants in BBS1 (−0.54 and −0.09, respectively), which was also aligned with change in weight across pediatric (BMI Z score reduction, −0.45 and −0.25, respectively) and adult (mean percent change in BMI, −16.4 and −6.2, respectively) patients. This evidence concerns the gene BBS10 and metabolic syndrome.